Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Immix Biopharma, Inc. (IMMX) had Return on Tangible Equity of -163.75% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-21.61M |
|
-- |
|
-- |
|
$22.67M |
|
$-22.67M |
|
$1.02M |
|
$-21.66M |
|
$-21.66M |
|
$-21.70M |
|
$-21.70M |
|
$-21.70M |
|
$-21.70M |
|
$-22.67M |
|
$-22.56M |
|
28.29M |
|
28.29M |
|
$-0.76 |
|
$-0.76 |
|
| Balance Sheet Financials | |
$20.20M |
|
$1.74M |
|
$2.75M |
|
$22.95M |
|
$8.69M |
|
-- |
|
$1.01M |
|
$9.70M |
|
$13.25M |
|
$13.25M |
|
$13.25M |
|
27.54M |
|
| Cash Flow Statement Financials | |
$-14.60M |
|
$-1.18M |
|
$15.95M |
|
$17.51M |
|
$17.68M |
|
$0.17M |
|
$3.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.33 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-15.77M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-163.75% |
|
|
Return on Tangible Equity |
-163.75% |
-94.56% |
|
-163.75% |
|
$0.48 |
|
$-0.56 |
|
$-0.52 |
|